Eli Lilly and Co. (LLY) has announced a significant investment of $364 million (approximately 279 million pounds) in the U.K.'s biotechnology sector through the establishment of Lilly Gateway Labs. This initiative will primarily concentrate on developing treatments like Mounjaro for diabetes and Zepbound for weight loss, aiming to address critical health issues. The announcement was made during the International Investment Summit on Monday.
In accordance with a memorandum of understanding with the U.K. government, Lilly has pledged to support emerging life sciences companies, although specific financial details of this investment remain undisclosed.
The newly founded Gateway Labs by Eli Lilly will offer both mentorship and financial support to these early-stage businesses.
Wes Streeting, the U.K.'s Health and Social Care Secretary, remarked, "This announcement underscores the U.K.'s position as a global leader in life sciences, bringing life-changing treatments closer to reality for NHS patients. Collaborations like these are essential for building a healthier society, a stronger economy, and ensuring the NHS is prepared for the future."
In 2023 alone, the life sciences sector has attracted 800 million pounds in foreign direct investment into the U.K.
